Opportunity Overview
The Maine Department of Health and Human Services, Maine CDC / Infectious Disease Surveillance / HIV Prevention, maintains an active Willing & Qualified contracting pathway for Syringe Service Programs. CT NOI 0320260186 covers the current service term through June 30, 2027.
The program supports expansion of Maine’s certified syringe service programs, including staffing, infectious-disease testing, referral and linkage to care, naloxone distribution, and physical program supplies such as syringes, prep supplies, filters, and HIV and Hepatitis C point-of-care rapid testing kits.
Current Funding and Providers
The current PJF lists a revised total of $3,875,659.58 across 11 provider agreements. The amendment adds $354,295.38 and supports two additional contracts plus an amendment to Spurwink’s agreement for the Lewiston service area following the closure of another program.
The current providers are Commonspace, Spurwink, Maine Access Points, Maine Recovery Access Project, Needlepoint Sanctuary, Wabanaki Health & Wellness, City of Portland, MaineGeneral Medical Center, MaineHealth dba Healthy Community Coalition, Coastal Recovery Community Center, and Opiate-Free Island Partnership. These named organizations are incumbent funded providers and are not treated as unsent applicants for this exact W&Q opportunity.
Eligibility and Qualification Requirements
Maine CDC states that providers must operate Certified Hypodermic Apparatus Exchange Programs in Maine and perform the work on a state-certified basis under applicable Maine law and rules. Funding is allocated based on factors including rates of intravenous drug use and related negative health outcomes in the surrounding geographic area, historical service volume where applicable, and other relevant factors.
The Department states that it does not intend to issue an RFP for these services because the work is offered to providers that are willing and qualified.
Atlas Relevance
This is a substantial public-health and harm-reduction contracting pathway with direct relevance to infectious-disease testing, linkage to care, naloxone distribution, and point-of-care rapid testing. The controlling PJF identifies physical program supplies and HIV/Hepatitis C point-of-care rapid testing kits as supported costs, but it does not establish remote-exam technology or N9+ costs as allowable. Those costs should not be inferred without specific written Maine CDC confirmation.
Dr. Miltie does not appear to be a viable direct prime provider under the current qualification model because the prime contractor must operate a state-certified syringe service program. A technology or clinical-support role should be evaluated only through a qualified certified provider and only where Maine CDC confirms the applicable cost treatment.
Next Action
Preserve the 11 named organizations as incumbent funded providers. For any prospective new provider, first verify active Maine certification as a syringe service program, current W&Q availability, geographic/service need, and funding availability with Maine CDC. Apply normal CRM, Atlas_Email_Queue, Email Opt-Out, sent-history, reply, bounce, deadline, approval, and organization+exact-opportunity deduplication controls before any outreach is queued.
Official source: Maine Division of Procurement Services, CT NOI 0320260186, Syringe Service Programs.